Target RWE at #AAD2025

Discover our real-world evidence solutions for dermatologic conditions and learn about upcoming activity at AAD

Explore Our Dermatology Data & Real-World Insights

Join Target RWE at the American Academy of Dermatology (AAD) annual meeting as we share new insights into dermatological research. Our team is proud to present two posters addressing important challenges in patient care including healthcare disparities and the burden of odor in patients with hidradenitis suppurativa (HS). View our activity below to see how our real-world evidence solutions are shaping the future of dermatology and skin diseases!

Meet Target RWE at #AAD2025

Schedule a Meeting

Pioneering Innovation & Research in Dermatology

"AAD is always a highlight, bringing together the leading minds in dermatology. I'm eager to collaborate and continue pushing the boundaries of research that ultimately improves patient care. I've loved seeing the tangible impact of the research presented here over the years, and I'm honored to be a part of it." Michael W. Fried, MD, FAASLD Co-Founder & Chief Medical Officer

Notable achievements:

Significant Growth & Scope: TARGET-DERM has grown substantially since 2019, becoming a comprehensive registry covering multiple dermatological conditions (AD, AA, HS, CSU, Vitiligo) with over 7,000 enrolled patients.
Comprehensive Data Capture: The study captures diverse data, including EMR data (structured and unstructured), patient-reported outcomes (PROMs), clinician-reported outcomes (ClinROs), and biosamples, supporting translational research and biomarker development.

Our Activity at AAD 2025

TARGET-DERM HS

Healthcare Disparities in Hidradenitis Suppurative in the US: TARGET-DERM HS

Poster #63120, Mar 08, 2025 9:40 AM - 9:45 AM

This study explores healthcare disparities in hidradenitis suppurativa using real-world data from the TARGET-DERM HS study. Researchers analyzed demographics, disease characteristics, and treatment patterns across racial and ethnic groups in US patients with HS.

TARGET-DERM HS

Characterization of Patient Perception of Odor Severity in Hidradenitis Suppurativa Using TARGET-DERM HS

Poster #64770, Mar 09, 2025 3:30 PM - 3:35 PM

This study explores the impact of odor on patients with hidradenitis suppurativa (HS), a chronic inflammatory skin disease. Using data from the TARGET-DERM HS study, researchers analyzed patient-reported odor severity and its association with clinical characteristics, patient-reported outcomes, and quality of life.

Booth 1885

Stop by and visit Target RWE's booth #1885 during AAD 2025 to learn more about our dermatology real-world data and publications!

Past Presentations Advancing Dermatological Research

Patient Reported Burden is Associated with Clinician-Reported Severity in Alopecia Areata: Real World Insights from TARGET-DERM AA

Patient-reported outcome measures (PROMs) data from the TARGET-DERM AA registry, presented at AAD 2024, confirm the significant unmet need and disease burden faced by individuals with moderate to severe alopecia areata (AA). As the largest and most comprehensive longitudinal real-world evidence (RWE) study of immune-mediated inflammatory skin conditions in the US, TARGET-DERM AA is uniquely positioned to investigate real-world access to care, disease progression, diagnosis, and treatment in AA patients.

The presented data, analyzing participant enrollment visits between December 2021 and July 2023, demonstrated a significant association between worsening clinician-reported outcomes, PROMs related to severity and quality of life, and increasing Severity of Alopecia Tool (SALT) scores.

Real-World Evidence on Atopic Dermatitis: Baseline Characteristics and Predictors of Treatment Choice in the TARGET Cohort

Target RWE research published in the Journal of the American Academy of Dermatology highlighted treatment trends in AD, revealing racial variances in how quality of life impacts systemic treatment decisions. TARGET-DERM's rich data, including a large pediatric AD cohort (45% of AD participants), is invaluable for understanding these conditions, informing treatment strategies, and improving patient outcomes.

TARGET-DERM: Unlocking the Power of Real-World Data in Dermatology Research

TARGET-DERM stands as a robust resource for dermatological research, fueled by real-world data reflecting the diversity of the U.S. population as captured by the U.S. Census. With data from over 7,000 patients across 35+ sites, our platform offers a comprehensive view of conditions like atopic dermatitis (AD), alopecia areata (AA), hidradenitis suppurativa (HS), chronic spontaneous urticaria (CSU), and vitiligo.

Beyond the wealth of information derived from electronic medical records, TARGET-DERM's strength lies in our ability to actively engage with sites and patients, enabling the collection of additional data points and insights that paint a more complete picture of the patient journey. This direct engagement, combined with the expertise of 12+ thought leaders and a growing body of 30+ publications, positions TARGET-DERM to drive impactful research and shape the future of dermatological care.

Learn More